Medicare Part D Redesign To Offset 2025 Growth, AbbVie Says

 
• By Joseph Haas

Expectations for Skyrizi, Rinvoq skyrocket, and while AbbVie expects to return to compound annual growth in the high single digits this year, the Medicare drug benefit redesign will cut revenue by about 4%.

AbbVie exterior
AbbVie expects Medicare Part D reworking to cut revenues by 4% this year • Source: Alamy

More from Earnings

More from Drug Pricing